CN110301647A - The compound oligomeric peptide nutrient food of ground dragon protein - Google Patents
The compound oligomeric peptide nutrient food of ground dragon protein Download PDFInfo
- Publication number
- CN110301647A CN110301647A CN201811438507.XA CN201811438507A CN110301647A CN 110301647 A CN110301647 A CN 110301647A CN 201811438507 A CN201811438507 A CN 201811438507A CN 110301647 A CN110301647 A CN 110301647A
- Authority
- CN
- China
- Prior art keywords
- oligopeptide
- parts
- vitamin
- dragon protein
- nutrient food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 21
- 235000013305 food Nutrition 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 title claims abstract description 16
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 14
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 58
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 58
- 239000000843 powder Substances 0.000 claims abstract description 19
- 241000237636 Pheretima Species 0.000 claims abstract description 16
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 14
- 241000251468 Actinopterygii Species 0.000 claims abstract description 13
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 13
- 241000237502 Ostreidae Species 0.000 claims abstract description 13
- 235000020636 oyster Nutrition 0.000 claims abstract description 13
- 235000020234 walnut Nutrition 0.000 claims abstract description 13
- 241000251511 Holothuroidea Species 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 16
- 235000019152 folic acid Nutrition 0.000 claims description 16
- 229960000304 folic acid Drugs 0.000 claims description 16
- 239000011724 folic acid Substances 0.000 claims description 16
- 241000758789 Juglans Species 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 10
- 235000013734 beta-carotene Nutrition 0.000 claims description 10
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 10
- 239000011648 beta-carotene Substances 0.000 claims description 10
- 229960002747 betacarotene Drugs 0.000 claims description 10
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 10
- -1 folic acid 2mg Chemical compound 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 229940000252 folic acid 2 mg Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- RMDJVOZETBHEAR-GHTRHTQZSA-N vitamin d5 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@H](CC)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C RMDJVOZETBHEAR-GHTRHTQZSA-N 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 23
- 206010008118 cerebral infarction Diseases 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 18
- 206010061216 Infarction Diseases 0.000 abstract description 15
- 230000007574 infarction Effects 0.000 abstract description 15
- 208000024891 symptom Diseases 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 5
- 208000019553 vascular disease Diseases 0.000 abstract description 3
- 240000007049 Juglans regia Species 0.000 abstract 1
- 239000000047 product Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 9
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 9
- 230000002526 effect on cardiovascular system Effects 0.000 description 8
- 229930003316 Vitamin D Natural products 0.000 description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 235000019166 vitamin D Nutrition 0.000 description 7
- 239000011710 vitamin D Substances 0.000 description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 description 7
- 229940046008 vitamin d Drugs 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000004089 microcirculation Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RMDJVOZETBHEAR-LQYWTLTGSA-N vitamin D5 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](CC)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C RMDJVOZETBHEAR-LQYWTLTGSA-N 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000018152 Cerebral disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 208000007442 rickets Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010004954 Birth trauma Diseases 0.000 description 1
- 208000019743 Cranial nerve injury Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010070324 lumbrokinase Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000018338 positive regulation of fibrinolysis Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000010010 raising Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to field of health care food, i.e. the compound oligomeric peptide nutrient food of dragon protein.It is suitble to heart infarction, cerebral infarction and all kinds of vascular diseases crowds to take.It is particularly suitable for suffering from the cytotrophy and reparation of oldness cerebral infarction, heart infarction patient.It is made of the raw material of following parts by weight: 15-35 parts of pheretima albumen powder, fish oligopeptide 5-35 parts of ocean, 5-15 parts of sea cucumber oligopeptide, 5-15 parts of oyster oligopeptide, 10-15 parts of Yak Bone oligopeptide, 5-15 parts of walnut oligopeptide and auxiliary material.To oldness heart infarction, cerebral infarction typical case 31 observations, all 31 cardinal symptoms disappear, energetic, get well, auxiliaring effect is significant.
Description
Technical field
The present invention relates to field of health care food, i.e. the compound oligomeric peptide nutrient food of dragon protein.It is suitble to heart infarction, cerebral infarction and all kinds of blood vessels
Sick people takes.It is particularly suitable for suffering from the cytotrophy and reparation of oldness cerebral infarction, heart infarction patient.
Background technique
In the prior art, heart infarction and cerebral infarction disease are the number one killers in diseases of cardiovascular and cerebrovascular systems, according to the Ministry of Public Health
Statistics are shown within 2007, and cardiovascular and cerebrovascular disease is with " disease incidence is high, disability rate is high, the death rate is high, high recurrence rate, concurrently
Disease is more " i.e. " more than four high one " the characteristics of, currently, China's Patients with Cardiovascular/Cerebrovascular Diseases alreadys exceed 2.7 hundred million people！China is dead every year
In nearly 3,000,000 people of cardiovascular and cerebrovascular disease, account for China every year total Death causes 51%.Meanwhile 40,50 years old or more the middle-aged and the old
It is unfavorable due to treating after many people's illness in group, cause to generate different degrees of disability and various sequelae.There are many more diseases
People bad life habits, due to operating pressure is excessive, health perception is weak etc., suffered from slight cardio-cerebral diseases relatively long and
Do not know, until when physical examination, be just found be in oldness cerebral infarction or heart infarction morbid state.Currently, cardio-cerebral diseases disease incidence removes
In outside large area ascendant trend in mid-aged population, even more noteworthy there is rejuvenation trend, more than 20 years old blueness having
Year people also suffers from heart infarction or cerebral infarction, in addition all rescue measures proved ineffectual and it is dead ....Oldness cerebral infarction, that is, brain tissue ischemia center is complete
Necrosis, the infarcted region therapeutic purposes Ying Shi perienchyma function continue to improve.There are higher recurrence wind for oldness cerebral infarction
Danger, so suffering from the patient of oldness cerebral infarction, treatment and prevention no less important should reduce symptom degree, reduce high relapse rate.
Therefore, in face of cardiovascular and cerebrovascular diseases such as heart infarction and cerebral infarctions, it is necessary to cause enough attention, actively reply be taken to arrange for morbidity root
It applies, seeks to prevent, treat the preferred plan and method with rehabilitation.Health care product has heart infarction, cerebral infarction and all kinds of vascular diseases crowds
Booster action, but health care product is many kinds of at present, curative effect is different.
Summary of the invention
The purpose of the present invention is providing a kind of ground dragon protein compound oligomeric peptide nutrient food in view of the above deficiencies, this product solution
Having determined, it is significant to suffer from oldness cerebral infarction, the cytotrophy of heart infarction patient and reparation problem, auxiliaring effect.
The technical solution of the invention is as follows: the compound oligomeric peptide nutrient food of ground dragon protein, it is characterised in that by following weight
The raw material of number forms: 15-35 parts of pheretima albumen powder, fish oligopeptide 5-35 parts of ocean, 5-15 parts of sea cucumber oligopeptide, oyster are oligomeric
5-15 parts of peptide, 10-15 parts of Yak Bone oligopeptide, 5-15 parts of walnut oligopeptide and auxiliary material.Auxiliary material is vitamin C, vitamin D, leaf
Acid, beta carotene.
It is preferred that the compound oligomeric peptide nutrient food of ground dragon protein, it is characterised in that be made of the raw material of following parts by weight: pheretima
Albumen powder 35g, ocean fish oligopeptide 15g, sea cucumber oligopeptide 15g, oyster oligopeptide 15g, Yak Bone oligopeptide 15g, walnut are low
Poly- peptide 5g, vitamin C 1g, 0 μ g of Vitamin D5, folic acid 2mg, beta carotene 5mg.
Dosage form be pulvis, granule or tablet, capsule, oral solution, but not limited to this.
Main material production producer: pheretima protein peptide powder, Xi'an Tong Ze biotechnology company commercially product.Foreign fish oligopeptide
Powder, commercially product, the oligomeric Gly-His-Lys of sea cucumber, Zhejiang oasis Bioisystech Co., Ltd commercially produce for Haikou former peptide biotechnology company
Product.The oligomeric Gly-His-Lys of oyster, commercially product, the oligomeric Gly-His-Lys of Yak Bone, Xi'an pool nation are biological for Zhejiang oasis Bioisystech Co., Ltd
Science and Technology Ltd.'s commercially product, the oligomeric Gly-His-Lys of walnut, Xi'an Bai Chuan biotechnology company commercially product.
This product is small-molecular peptides monoid product of new generation, small point of composite collagen formed through reasonable, optimum organization
Sub- peptide group has effects that human body more fully nutritional supplementation, small-molecular peptides monoid is by a variety of from not homologous protein carrier
The oligopeptide that animals and plants are produced respectively using biological enzymolysis technology, the oligopeptides mixture formed through reasonable compatibility, overcomes list
The characteristics of a kind of micromolecular peptide trophism is short of, realizes trophism bigizationner to cell, activation, inhibit, repair and
The effect for improving cell is more significant.
Small-molecular peptides monoid has oligopeptides huge number, the amino acid classes of component peptide and microelement abundant, is more suitable for
Numerous features, the average molecular weight such as absorption of human body use are generally less than 700D, to the inhibition of body cell, activation, reparation, improvement
Effect is more comprehensively, more rapidly.
Compound oligopeptide solid beverage is by ocean Rofe fish oligopeptide powder (belonging to water), the oligomeric Gly-His-Lys of walnut (belonging to wood), sea
Join oligomeric Gly-His-Lys (belonging to fire), the oligomeric Gly-His-Lys of yak (dependent territory), the oligomeric Gly-His-Lys of oyster (belonging to gold) and Vc, VD, folic acid, β-carrot
The compatibilities such as element form, theoretical according to the yin-yang and five elements interpromoting relation in five elements of " harmony between man and nature ", select attribute for water, wood, fire, soil, five kinds of gold
Oligopeptide, the needs that corresponding human five internal organs' six internal organs mutually support mend peptide effect more comprehensively, rapidly, rationally to human body.Meanwhile by
In containing Vc, VD, folic acid, beta carotene etc., promote organism physiology effect more prosperous and more powerful.This product is hormone-free, heavy metal and agriculture
Residual hazard, suitable all groups take.
Pheretima albumen powder contains clostridiopetidase A, fibrinolysin, Lumbrokinase, activation of fibrinolysis albumen (FA albumen), nucleic acid, microelement
Equal Multiple components, molecular weight belong to short chain small-molecule substance in 5000-10000D.Ground dragon protein main function is extension body
Interior thrombosis and the internal thrombus of dissolution, improve microcirculation, promote capilary regeneration, establish offshoot circulation, are the heart of focal zone
Brain tissue opens up new blood access, repairs the cranial nerve cell of necrosis, cures hemiplegia, thus achieve the effect that lasting thrombolysis,
The rehabilitation of prevention to cardiovascular and cerebrovascular diseases, apoplexy sequelae is significant.Facilitate to eliminate again simultaneously related with microcirculation disorder
Aging and tumour occur, improve whole body various physiological-function and health status, improve immunity, reduce by the three high danger to human body
Evil.Experiments have shown that: ground dragon protein is safe and non-toxic, long-term consumption will not generate ill-effect to human body.2009, the Ministry of Public Health 2009
Year, No. 18 text approval ground dragon protein was as new resource food.
Pheretima albumen powder, pheretima albumen powder have high bio-energy and bioactivity, can be greatly improved to blood
The penetrability and thrombolysis of brain barrier and the power of regeneration for promoting cell, examined by " microcirculation tester ": pheretima albumen powder can
To be obviously improved microcirculation in human body state, accelerate blood flowing speed.
Ocean fish oligopeptide, sea cucumber oligopeptide, oyster oligopeptide, Yak Bone oligopeptide, walnut oligopeptide monoid are to use
The state-of-the-art low-temperature biological directional enzymatic technology removal fat in the world, purine substance, prepare small-molecular-weight (average <
Oligomeric Gly-His-Lys 700D), have solubility 100%, absorptivity 100%, bioavilability 100%, no hormone, without agriculture it is residual degree and have
Evil heavy metal, it is safe and reliable, without any side effects, it is the ingredient of novel nutritious and healthy food.
Vitamin C is a kind of maximum vitamin vitamin of human body requirement.
Vitamin C have a series of physiological function, once had omnipotent vitamin in history " reputation, have enhancing human body exempts from
Epidemic disease function prevents and treats hypoferric anemia, pernicious anaemia, scurvy effect, can promote the formation of collagen and the generation of steroids
It thanks, is conducive to the integrality for maintaining the normal function of bone and tooth, maintaining cell membrane, there is removing toxic substances to make certain noxious materials
With also with anti-aging effects and cancer-resisting effect.
Folic acid is the patron saint of life.
The middle-aged and the old is also the key population of Supplement of folic acid.
1. reducing risk of stroke
Data are shown: China resident folic acid deficiency ratio is up to 20% ~ 60%.Human body lacks the intake of folic acid, is easy to cause blood
In content of homocysteine increase, raisings of this substance will result directly in headstroke occur probability ramp.
Folic acid can improve function of vascular endothelium, the chronic cardiovasculars disease such as prevention coronary heart disease.Combined by Sino-U.S. physician
At research confirm that Supplement of folic acid can effectively reduce the risk of cerebral apoplexy.
2. preventing senile dementia
For the middle-aged and the old, sufficient folic acid not only can be reduced internal harmful substance to cerebrovascular damage, additionally aid
Reduce the decline of cognitive ability caused by Cranial nerve injury as birth trauma and senile dementia.
3. folic acid sleeping improves memory
Once lacking folic acid, the resistance of human body will weaken, and can show apathetic, fatigue and weak, insomnia forgetfulness, appetite and subtract
It moves back, there are also glossitis, diarrhea, pernicious anaemia, children and the elderlys drowsiness or amentia often occurs by some people.
Usually our about 300 micrograms of folic acid for obtaining from food daily, will play prevention effect, preferably additional supplement
200 micrograms.Fearful, the people for lacking folic acid does not have particularly apparent symptom, if but they simultaneously with hypertension,
So the risk of apoplexy will improve 12 times！Folic acid be to human body it is universal beneficial, even without hypertension, sufficiently intake leaf
Acid can also greatly reduce the probability of happening of headstroke.
The effect of vitamin D can not be underestimated.
Show to be deficient in vitamin D may be extremely harmful to body for more and more evidences in recent years.It is thought that dimension life
Plain D is in addition to preventing and treating the rickets of children and the rickets of adult, arthralgia etc. is outer, right for forming and maintaining the strong of bone
Colon cancer, the probability of breast cancer and prostate cancer are reduced, also has humidification to immune system.Heart American scientist one schedules to last
40 years the study found that it is daily take one vitamin D can suffer from breast cancer, colon cancer and oophoroma risk reduce by one
Half.The diseases such as heart disease, tuberculosis, cancer, diabetes, hypertension, schizophrenia and multiple sclerosis, which are formed, all to be tieed up with shortage
Raw element D is closely related, and the effect of vitamin D can not be underestimated.
Specification: 3.5g/ bags × 15 bags/box, 1000g/ bags (solid beverage).
Usage and dosage: it is each primary daily morning and evening, 1 bag every time, every bag of 3-5g, drink-service is dissolved with 150-200ml warm water, it can be normal
Year takes.
Preparation method: by formula ratio that pheretima protein peptide powder and ocean fish oligopeptide powder, sea cucumber oligopeptide, oyster is oligomeric
Peptide, Yak Bone oligopeptide, walnut oligopeptide, vitamin C, vitamin D, folic acid, beta carotene merging mixing machine are sufficiently mixed
After uniformly, metering, distributing, packaging.
The invention has the advantages that 1, pheretima albumen powder has high bio-energy and bioactivity, it is greatly improved to blood
The penetrability and thrombolysis of brain barrier and the power of regeneration for promoting cell, examined by " microcirculation tester ": pheretima albumen powder can
To be obviously improved microcirculation in human body state, accelerate blood flowing speed.Compatibility ocean fish oligopeptide, sea cucumber oligopeptide, oyster are low
Poly- peptide, Yak Bone oligopeptide, walnut oligopeptide and vitamin C, vitamin D, folic acid, beta carotene etc., especially to oldness
Heart infarction, cerebral infarction and all kinds of vascular diseases have reverse, rehabilitation and preventive effect very well.2, it is provided to suffer from cardiovascular and cerebrovascular disease crowd
Nutrition recuperating Special product, there is the features such as targeting is strong, definite effect, and relatively economical is applicable in.3, Tonghua, Jilin Province Kang Yuan is cured
Medicine research institute is using this product (solid beverage) to oldness heart infarction, cerebral infarction typical case 31 observations, whole 31 cardinal symptoms
It disappears, it is energetic, it gets well, auxiliaring effect is significant.
Embodiments of the present invention are described in further detail below in conjunction with embodiment.
Specific embodiment
Embodiment 1
The compound oligomeric peptide nutrient food of ground dragon protein, it is characterised in that be prepared from the following raw materials in parts by weight: pheretima albumen powder
35g, ocean fish oligopeptide 15g, sea cucumber oligopeptide 15g, oyster oligopeptide 15g, Yak Bone oligopeptide 15g, walnut oligopeptide 5g,
Vitamin C 1g, 0 μ g of Vitamin D5, folic acid 2mg, beta carotene 5mg.
Embodiment 2
The compound oligomeric peptide nutrient food of ground dragon protein, it is characterised in that be prepared from the following raw materials in parts by weight: pheretima albumen powder
25g, ocean fish oligopeptide 25g, sea cucumber oligopeptide 15g, oyster oligopeptide 15g, Yak Bone oligopeptide 15g, walnut oligopeptide 5g,
Vitamin C 1g, 0 μ g of Vitamin D5, folic acid 2mg, beta carotene 5mg.
Embodiment 3
The compound oligomeric peptide nutrient food of ground dragon protein, it is characterised in that be prepared from the following raw materials in parts by weight: pheretima albumen powder
15g, ocean fish oligopeptide 35g, sea cucumber oligopeptide 15g, oyster oligopeptide 15g, Yak Bone oligopeptide 15g, walnut oligopeptide 5g,
Vitamin C 1g, 0 μ g of Vitamin D5, folic acid 2mg, beta carotene 5mg.
Experimental example:
Tonghua, Jilin Province Kang Yuan institute of Pharmaceutical Research is using this product (solid beverage) to oldness heart infarction, cerebral infarction typical case 31 sights
It examines, all 31 cardinal symptoms disappear, and it is energetic, it gets well, significant effect.Specific case provides as follows:
(1) Qu Nvshi, female, 70 years old, oldness cerebral infarction, giddy, dizziness, limb adynamia, take this product (solid beverage) 1 year, main
Symptom is wanted to disappear, energetic, stride is strong and vigorous.
(2) Mr. Zhang, male, 65 years old, oldness heart infarction, shortness of breath uncomfortable in chest, it is weak all over.Take the ground compound oligopeptide of dragon protein
Nutriment (solid beverage) 10 months, cardinal symptom disappear, get well, and division header issues the existing obvious physiology black by leucismus and becomes
Change.
Claims (4)
1. the compound oligomeric peptide nutrient food of ground dragon protein, it is characterised in that be made of the raw material of following parts by weight: pheretima albumen powder
15-35 parts, fish oligopeptide 5-35 parts of ocean, 5-15 parts of sea cucumber oligopeptide, 5-15 parts of oyster oligopeptide, Yak Bone oligopeptide 10-
15 parts, 5-15 parts of walnut oligopeptide and auxiliary material.
2. the compound oligomeric peptide nutrient food of ground described in accordance with the claim 1 dragon protein, it is characterised in that auxiliary material is vitamin C, dimension
Raw element D, folic acid, beta carotene.
3. the compound oligomeric peptide nutrient food of ground according to claim 1 or 2 dragon protein, it is characterised in that by following parts by weight
Raw material composition: pheretima albumen powder 35g, ocean fish oligopeptide 15g, sea cucumber oligopeptide 15g, oyster oligopeptide 15g, Yak Bone are low
Poly- peptide 15g, walnut oligopeptide 5g, vitamin C 1g, 0 μ g of Vitamin D5, folic acid 2mg, beta carotene 5mg.
4. the compound oligomeric peptide nutrient food of ground described in accordance with the claim 3 dragon protein, it is characterised in that dosage form is pulvis, granule
Or tablet, capsule or oral solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811438507.XA CN110301647A (en) | 2018-11-29 | 2018-11-29 | The compound oligomeric peptide nutrient food of ground dragon protein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811438507.XA CN110301647A (en) | 2018-11-29 | 2018-11-29 | The compound oligomeric peptide nutrient food of ground dragon protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110301647A true CN110301647A (en) | 2019-10-08 |
Family
ID=68074188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811438507.XA Pending CN110301647A (en) | 2018-11-29 | 2018-11-29 | The compound oligomeric peptide nutrient food of ground dragon protein |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110301647A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110652010A (en) * | 2019-11-01 | 2020-01-07 | 辽宁太爱肽生物工程技术有限公司 | Peptide-containing composition for gastrointestinal non-ideal crowd and application thereof |
| CN114916677A (en) * | 2022-04-18 | 2022-08-19 | 沈阳药大生物科技有限公司 | Oligopeptide composition for improving cell health condition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101418037A (en) * | 2008-11-14 | 2009-04-29 | 华子昂 | Yak bone peptide and preparation method thereof |
| CN102077940B (en) * | 2010-09-20 | 2013-04-24 | 王强 | Special dietary marine food for patients with coronary heart disease |
| CN104208654A (en) * | 2014-09-05 | 2014-12-17 | 洛阳华以生物工程有限公司 | Healthcare prescription mainly containing earthworm protein extract |
| CN105476030A (en) * | 2015-12-15 | 2016-04-13 | 北京天肽生物科技有限公司 | Multi-functional composite oligopeptide nutrition powder |
-
2018
- 2018-11-29 CN CN201811438507.XA patent/CN110301647A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101418037A (en) * | 2008-11-14 | 2009-04-29 | 华子昂 | Yak bone peptide and preparation method thereof |
| CN102077940B (en) * | 2010-09-20 | 2013-04-24 | 王强 | Special dietary marine food for patients with coronary heart disease |
| CN104208654A (en) * | 2014-09-05 | 2014-12-17 | 洛阳华以生物工程有限公司 | Healthcare prescription mainly containing earthworm protein extract |
| CN105476030A (en) * | 2015-12-15 | 2016-04-13 | 北京天肽生物科技有限公司 | Multi-functional composite oligopeptide nutrition powder |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110652010A (en) * | 2019-11-01 | 2020-01-07 | 辽宁太爱肽生物工程技术有限公司 | Peptide-containing composition for gastrointestinal non-ideal crowd and application thereof |
| CN114916677A (en) * | 2022-04-18 | 2022-08-19 | 沈阳药大生物科技有限公司 | Oligopeptide composition for improving cell health condition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101695382A (en) | Calcium supplementing preparation with functions of improving bones and joints | |
| CN102178934B (en) | Preparation for increasing bone mineral density, preventing osteoarthrosis and enhancing immunity | |
| CN101711786B (en) | Preparation used for relieving osteoarthropathy and enhancing immunity | |
| CN106418545A (en) | Functional food with balanced nutrients | |
| CN102726732A (en) | Nutritional supplement of foods for controlling cardiovascular disease, and its application | |
| CN103750310A (en) | Plant-sourced calcium capable of supplementing calcium and promoting calcium absorption and preparation method thereof | |
| CN103431392A (en) | Composite marine food for special dietary uses for diabetics | |
| CN110301647A (en) | The compound oligomeric peptide nutrient food of ground dragon protein | |
| CN103599137A (en) | Health food containing plurality of trace nutrient elements | |
| CN105768108A (en) | Special dietary food suitable for taking of tumor patients | |
| RU2309751C1 (en) | Method for treating the disorders of mineral metabolism at arthritis, or osteochondrosis, or rickets, or arthrosis, or osteoporosis | |
| CN102972672A (en) | Drug composite effervescent granule for supplementing nutrition and preparation method thereof | |
| CN101081281A (en) | Anti-fatigue resistibility capsules for improving body immunity and method for making same | |
| KR20080090808A (en) | Composition of healthy food for a skin | |
| KR101642176B1 (en) | Composition for enhancing growth and reinforcing immunity | |
| CN108815505A (en) | Improve the composition that middle-aged and the old's bone density and osteoarticular function avoid waist-leg from knotting | |
| CN107969596A (en) | A kind of holothurian freeze-dried powder solid beverage | |
| US20180169071A1 (en) | Nutritional supplement composition | |
| CN108371709A (en) | Lycium ruthenicum tumor recovering gene enzyme | |
| KR102480311B1 (en) | The manufacturing method of making healthcare food composition for costitutional group | |
| CN103690564A (en) | Application of wood frog high protein calcium powder in preparation of anti-fatigue health-care products or drugs | |
| CN107772455A (en) | A kind of composition tonified the kidney and support yang containing saline cistanche and instant reconstitute powder | |
| CN103933146A (en) | Pollen product capable of adjusting human body immunity | |
| CN101007127A (en) | A compound male silk moth health wine for male and processing method | |
| KR101169931B1 (en) | Health supplement comprising wild―peach powder as a staple ingredient and the manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191008 |
|
| RJ01 | Rejection of invention patent application after publication |